Clinical Trial Update: mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating everolimus-based immunosuppressive regimens to minimize calcineurin inhibitors in older kidney transplant recipients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Transplant

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: University Hospital, Brest | Conditions: Renal Transplant | Phase 3 | Status: COMPLETED